142 related articles for article (PubMed ID: 21606538)
1. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients.
Reiberger T; Payer BA; Kosi L; Heil PM; Rieger A; Peck-Radosavljevic M;
J Infect Dis; 2011 Jun; 203(12):1802-6. PubMed ID: 21606538
[TBL] [Abstract][Full Text] [Related]
2. Short communication: impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Milazzo L; Foschi A; Mazzali C; Viola A; Ridolfo A; Galli M; Antinori S
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):989-93. PubMed ID: 22220723
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
[TBL] [Abstract][Full Text] [Related]
4. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
5. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
[TBL] [Abstract][Full Text] [Related]
6. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
[No Abstract] [Full Text] [Related]
9. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
Valerio L; Yazdanpanah Y; Poizot-Martin I; Rosenthal E; Marimoutou C; Gastaut JA; Tran A; Dellamonica P; Freedberg KA; Pradier C
J Acquir Immune Defic Syndr; 2008 Jan; 47(1):50-5. PubMed ID: 18156991
[TBL] [Abstract][Full Text] [Related]
10. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
[TBL] [Abstract][Full Text] [Related]
11. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
[TBL] [Abstract][Full Text] [Related]
14. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
[TBL] [Abstract][Full Text] [Related]
15. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Opravil M; Sasadeusz J; Cooper DA; Rockstroh JK; Clumeck N; Clotet B; Montaner J; Torriani FJ; Depamphilis J; Dieterich DT
J Acquir Immune Defic Syndr; 2008 Jan; 47(1):36-49. PubMed ID: 18156990
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
[TBL] [Abstract][Full Text] [Related]
17. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
18. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
[TBL] [Abstract][Full Text] [Related]
19. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
